Breadcrumb

[A16-42] Saxagliptin - Benefit assessment according to §35a Social Code Book V

Overview

Overview

Commission: Commission awarded on 2016-07-04 by the Federal Joint Committee (G-BA)
Status:Commission completed
Department/Division:Drug Assessment
Current document:PDF Extract of dossier assessment  [PDF, 251 kB]Further documents
Note:

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

Contact address:to the contact form
Linked projects: [A16-71] Saxagliptin + saxagliptin/metformin (Addendum to Commission A16-42 + A16-43)
Status: Commission completed

[A13-32] Saxagliptin - Benefit assessment according to § 35a Social Code Book V (dossier assessment)
Status: Commission completed

[A13-12] Saxagliptin/metformin - Benefit assessment according to § 35a Social Code Book V (dossier assessment)
Status: Commission completed

[A13-01] Saxagliptin - Benefit assessment according to § 35a Social Code Book V (dossier assessment)
Status: Commission completed


Report documents

Report documents

PublishedDocumentSizeType 
2016-10-04 Extract of dossier assessment 251 kBPDFdownload file
2016-10-04 Dossier assessment (German version) 2 MBPDFdownload file

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.


At a glance

Accompanying information

Extract of dossier assessment

  File-Icon  Saxagliptin - Benefit assessment according to §35a Social Code Book V [PDF, 251 kB]

Federal Joint Committee (G-BA)

2016-12-15 A G-BA decision was published.

G-BA documents on this decision

Press releases

2016-10-04 Saxagliptin and saxagliptin/metformin in type 2 diabetes: added benefit not proven



Save result list

To save your search result, please copy the link below and paste it into a new tab/window.

close